Free Trial

NeoGenomics Q1 2024 Earnings Report

NeoGenomics logo
$9.90 -0.50 (-4.76%)
As of 02:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NeoGenomics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

NeoGenomics Revenue Results

Actual Revenue
$156.24 million
Expected Revenue
$149.82 million
Beat/Miss
Beat by +$6.42 million
YoY Revenue Growth
N/A

NeoGenomics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

NeoGenomics Earnings Headlines

Piper Sandler Remains a Buy on NeoGenomics (NEO)
NeoGenomics price target lowered to $18 from $21 at Piper Sandler
FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
BTIG Sticks to Their Buy Rating for NeoGenomics (NEO)
NeoGenomics to Participate in Upcoming Investor Conferences
Q1 Earnings Estimate for NeoGenomics Issued By William Blair
See More NeoGenomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

View NeoGenomics Profile

More Earnings Resources from MarketBeat